irbesartan Articles
Watson gets FDA approval for generic Sanctura XR and Avapro
14 October 2012
Sanofi buys Colombian drugmaker; Presents encouraging eliglustat and Lyxumia data; Revizes deal with B-MS
3 October 2012
Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
1 April 2012
Sanofi-Aventis says strong swine flu vaccine sales in 4th quarter will drive higher earnings
30 October 2009
Malaysian govt encouraging biotech sector of pharma market
22 October 2009
Sanofi relocates plant to Binjiang
22 April 2009
Bristol-Myers Squibb an attractive value
14 April 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
EC delays decision on Sanofi/Zentiva merger
26 January 2009
Shionogi profit jumps 10% on Crestor sales
8 December 2008
List of new CHMP drug recommendations
6 October 2008
Flat pharma sales reported in Japan
29 September 2008
Japan stock market week to August 4, 2008
11 August 2008
Japan stock market week to June 30, 2008
7 July 2008
ARB switching strategy may not result in long-term savings within a five-year model, says Merck & Co
12 May 2008
Sanofi-Aventis
5 May 2008
Japan stock market week to Aril 21, 2008
28 April 2008
Japan stock market week to Mar 3, 2008
10 March 2008
Pharmacopeia intitiates Ph IIb trial of DARA drug
10 March 2008
FDA clears Avalide as initial high BP therapy
26 November 2007
Japan stock market week to March 5, 2007
12 March 2007
B-MS swings to loss in 4th qtr due to Plavix
5 February 2007
Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results
6 November 2006
Sanofi-Aventis "on track" in Hungary
23 October 2006
EC approves S-A/B-MS' combo antihypertensive
11 September 2006
Japan stock market week to July 31, 2006
7 August 2006
B-MS's earnings hit $714M in 1st-qtr
8 May 2006
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
Sanofi's sales +18% to 2.2B euros for 1st-qtr
26 April 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
Sanofi-Synthelabo's 2003 sales up 15.6%
26 January 2004
B-MS ups forecast on strong 3rd quarter
3 November 2003
Sanif-Synthelabo opens new $20M irbisartan plant in Hungary
27 October 2003
Sanofi sales strong but below expectations
27 October 2003
UPDATE: B-MS beats forecasts in 2nd qtr
4 August 2003
Sales up 14% at Sanofi-Synthelabo in 1st half
28 July 2003
Sanofi-Synthelabo 1st qtr below consensus
5 May 2003
53.7% US sales leap boosts Sanofi-Synthelabo
27 January 2003
B-MS provides 2003 earnings guidance
27 January 2003
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
Sanofi-Synthelabo 1st-half sales up 14.8%
29 July 2002
B-MS turnover down 14% in 2nd quarter
29 July 2002
Irbesartan set for new indication in Europe
25 March 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
Stock Commentary - Europe
11 February 2002
B-MS/Sanofi withdraw Avapro filing
11 February 2002
Sanofi's Avapro fails to pass panel review
28 January 2002
Hypertension market set for major change.
21 January 2002
FDA backs Avapro use in diabetic renal disease.
21 January 2002
Hypertension market prospects to 2010
13 December 2001
France's Sanofi-Synthelabo continues to outperform competitors
26 October 2001
B-MS earnings driven by Glucophage
24 October 2001
Sanofi-Synthelabo first-half net income rises 50% - UPDATE
6 September 2001
Supplementals filed for irbesartan outside hypertension
14 August 2001
Sanofi-Synthelabo 1st-half sales up 15%
30 July 2001
Sanofi-Synthelabo 1st-half sales up 15%
27 July 2001
Stock Commentary - Europe
14 June 2001
Sanofi-Synthelabo ups rights on Avapro
8 June 2001
Sanofi-Synthelabo profits to rise 30%
24 May 2001
Blockbusters propel Sanofi-Synthelabo
25 April 2001
Sanofi-Synthelabo net earnings increase 54% for 2000
21 February 2001
Patients stay with irbesartan more than other antihypertensives
29 January 2001
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
